Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions

Kaipeng Zhou^#¹, Chen Lou^#², Po-Han Chang^#³, Jingjing Jiang⁴, Yue Zhao^{5

6

7

8}, Hsun-Ming Chang⁹, Liangshan Mu¹⁰

Affiliations

¹ Reproductive Medicine Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
² The First Clinical Medical College (School of Information and Engineering), Wenzhou Medical University, Wenzhou, China.
³ Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.
⁴ Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. jiang.jingjing@zs-hospital.sh.cn.
⁵ State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁶ National Clinical Research Center for Obstetrics and Gynecology, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁷ Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁸ Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁹ Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan. 037841@tool.caaumed.org.tw.
¹⁰ Reproductive Medicine Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. mu.liangshan@zs-hospital.sh.cn.

^# Contributed equally.

Kaipeng Zhou et al. Nat Rev Endocrinol. 2025 Aug.

. 2025 Aug;21(8):455-456.

doi: 10.1038/s41574-025-01121-z.

Kaipeng Zhou^#¹, Chen Lou^#², Po-Han Chang^#³, Jingjing Jiang⁴, Yue Zhao^{5

6

7

8}, Hsun-Ming Chang⁹, Liangshan Mu¹⁰

¹ Reproductive Medicine Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
² The First Clinical Medical College (School of Information and Engineering), Wenzhou Medical University, Wenzhou, China.
³ Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.
⁴ Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. jiang.jingjing@zs-hospital.sh.cn.
⁵ State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁶ National Clinical Research Center for Obstetrics and Gynecology, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁷ Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁸ Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China. zhaoyue_bysy@bjmu.edu.cn.
⁹ Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan. 037841@tool.caaumed.org.tw.
¹⁰ Reproductive Medicine Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. mu.liangshan@zs-hospital.sh.cn.

^# Contributed equally.

No abstract available

References

1. Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J. & Bellanger, D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil. Steril. 118, 371–381 (2022). - PubMed
1. Sanchez-Garrido, M. A. et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nat. Commun. 15, 8498 (2024). - PubMed - PMC
1. Lempesis, I. G. et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes Metab. Res. Rev. 39, e3682 (2023). - PubMed
1. Rakic, D. et al. Multiple benefits of empagliflozin in PCOS: evidence from a preclinical rat model. Pathophysiology 31, 559–582 (2024). - PubMed - PMC
1. Lin, B. et al. Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome. Eur. J. Pharmacol. 977, 176742 (2024). - PubMed